Treatment of Primary Chronic Glomerulonephritis with Rehmannia Glutinosa Acteosides in Combination with the Angiotensin Receptor Blocker Irbesartan: A Randomized Controlled Trial
Authors:
- 21 March 2013
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 28 (1) , 132-136
Abstract
This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis. A total of 479 patients diagnosed with primary chronic glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (Rehmannia glutinosa acteosides, two 200‐mg capsules, bid; and irbesartan, one 150‐mg tablet, qd) or the control group (irbesartan, one 150‐mg tablet, qd). The primary outcome was 24‐h urinary protein. Secondary outcome measures included blood pressure, estimated glomerular filtration rate, erythrocyturia, serum alanine aminotransferase, aspartate transaminase and electrolytes. After 8 weeks of treatment, the treatment group showed a mean reduction in 24‐h proteinuria of 36.42% compared to baseline, which was significantly higher than the mean reduction from baseline of 27.97% in the control group (P = 0.0278).Adverse drug reactions occurred at a similarly low rate in the treatment group (0.4%) and control group (1.2%, P = 0.3724). In the treatment of chronic glomerulonephritis, the combination of Rehmannia glutinosa acteosides and irbesartan can reduce proteinuria more effectively than irbesartan alone. Copyright © 2013 John Wiley & Sons, Ltd.Keywords
This publication has 11 references indexed in Scilit:
- Prevalence of chronic kidney disease in China: a cross-sectional surveyThe Lancet, 2012
- Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trialsEuropean Heart Journal, 2011
- Combination Therapy With an Angiotensin Receptor Blocker and an ACE Inhibitor in Proteinuric Renal Disease: A Systematic Review of the Efficacy and Safety DataAmerican Journal of Kidney Diseases, 2006
- Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent GlomerulosclerosisThe American Journal of Pathology, 2006
- Amelioration of Diabetic Nephropathy by Dried Rehmanniae Radix (Di Huang) ExtractThe American Journal of Chinese Medicine, 2004
- Management of Glomerular ProteinuriaJournal of the American Society of Nephrology, 2003
- Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritisKidney International, 2003
- Angiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis11See Editorial by de Zeeuw, p. 1176.Kidney International, 2002
- Renal Protective Effects of Blocking the Intrarenal Renin-Angiotensin System: Angiotensin II Type I Receptor Antagonist Compared with Angiotensin-Converting Enzyme Inhibitor.Hypertension Research, 2000
- The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.Journal of the American Society of Nephrology, 1998